A collaborative effort is trying to construct the cell atlas of the developing brains of humans and animal models. Using advanced single-cell and spatial technologies, they mapped how brain cell types emerge, diversify and organize over time, offering new insights into the origins of neurodevelopmental and psychiatric conditions. These breakthroughs in genomics and imaging will allow scientists to study complex developmental processes with high resolution. Read More
Neok Bio Inc. was formed earlier this year and is already on schedule to file an IND in a few months for its two bispecific antibody-drug conjugates (ADCs) to treat various types of tumors. The biotech got a leg up on development from its principal investor, Korean biotech ABL Bio Inc., where the discovery work was accomplished. Read More
Researchers at Crossbridge Bio Inc. have conducted preclinical evaluation of CBB-120, a novel TROP2-directed dual-payload ADC designed to combine TOP1i and ATR inhibitor (ATRi) mechanisms for enhanced therapeutic efficacy. Read More
Montse Rosa Therapeutics Inc. has developed a molecular glue degrader named MRT-2359 that selectively degrades the translation termination factor ERF3A. Read More
A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications during the quarter. Read More
Editor Annette Boyle discusses the challenges med-tech companies face in bringing innovation to market and how the industry can overcome them. Read More
Eilean Therapeutics LLC has presented in vivo data for its first-in-class MALT1 degrader, TE-205, as a disease-modifying therapy for ulcerative colitis. Read More
Scientists at Apichope Bio Pharmaceutical Co. Ltd., Apichope Pharmaceutical Co. Ltd., Guangzhou Lianrui Pharmaceutical Co. Ltd. and Guangzhou Runlin Pharmaceutical Technology Co. Ltd. have synthesized sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers potentially useful for the treatment of pain, arrhythmia, cough, multiple sclerosis, urinary incontinence and Charcot-Marie-Tooth disease. Read More
Adaptor protein-2 associated kinase 1 (AAK1) is key in clathrin-mediated endocytosis, which diverse viruses hijack in order to infect cells. Inhibiting AAK1 has been shown to block the entry of hepatitis C, dengue and rabies viruses into cells. Read More
Accutar Biotechnology Inc. recently presented preclinical data on AC-4847, a first-in-class PI3Kα-targeting degrader-antibody conjugate (DAC) designed for selective treatment of PI3Kα-driven cancers. Read More
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged pentacyclic derivatives reported to be useful for the treatment of autoimmune disease. Read More
Acrivon Therapeutics Inc. has developed a new WEE1/PKMYT1 inhibitor, ACR-2316, to overcome the limitations observed with previous WEE1 and PKMYT1 inhibitors in the treatment of cancer. Read More
Simcere Pharmaceutical Co. Ltd. has described stachybotrys microspore triprenyl phenols (SMTPs) acting as plasminogen activators reported to be useful for the treatment of thromboembolism. Read More
